Telithromycin: visual disorders, myasthenia. Case fatalities: this macrolide has a negative risk-benefit balance; its use not justified.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D005060:Europe; D006801:Humans; D048628:Ketolides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000139:chemically induced*; D014481:United States; D014786:Vision Disorders / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D048628:Ketolides